Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Vivani Medical And 2 Other Stocks Under $5 Insiders Are Buying

Author: Avi Kapoor | January 04, 2024 07:34am

The Dow Jones index closed lower by around 285 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Vivani Medical

  • The Trade: Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired a total of 7,111 shares an average price of $1.01. To acquire these shares, it cost around $7,182.
  • What’s Happening: Vivani Medical, during November, posted a wider-than-expected quarterly loss.
  • What Vivani Medical Does: Vivani Medical Inc is a preclinical stage biopharmaceutical company.

Harvard Apparatus Regenerative Technology

  • The Trade: Harvard Apparatus Regenerative Technology Inc. (OTC:HRGN) CEO Junli He acquired a total of 2,700 shares at at an average price of $4.76. To acquire these shares, it cost around $12,852.
  • What’s Happening: Harvard Apparatus Regenerative Technology announced that it officially executed a sponsored research agreement with Drs. Stephen Badylak, George Hussey and Vincent Anto at the McGowan Institute for Regenerative Medicine, a center of the University of Pittsburgh and UPMC focused on developing regenerative therapies to address organ and tissue failure.
  • What Harvard Apparatus Regenerative Technology Does: Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects.

Check This Out: Top 3 Industrials Stocks That Could Blast Off In Q1

CURO Group

  • The Trade: CURO Group Holdings Corp. (NYSE:CURO) CEO Douglas Clark acquired a total of 10,000 shares at an average price of $0.85. The insider spent around $8,479 to buy those shares.
  • What’s Happening: CURO Group Holdings, during November, posted weak quarterly results.
  • What CURO Group Does: CURO Group Holdings Corp is a consumer finance company serving a full spectrum of non-prime, near-prime and prime consumers in portions of the U.S. and Canada.

 

Don’t forget to check out our premarket coverage here

Posted In: CURO HRGN VANI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist